APA (7th ed.) Citation

Barry, H., Mutua, G., Kibuuka, H., Anywaine, Z., Sirima, S. B., Meda, N., . . . group, t. E. S. (2021). Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa. Public Library of Science (PLoS).

Chicago Style (17th ed.) Citation

Barry, Houreratou, et al. Safety and Immunogenicity of 2-dose Heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccination in Healthy and HIV-infected Adults: A Randomised, Placebo-controlled Phase II Clinical Trial in Africa. Public Library of Science (PLoS), 2021.

MLA (8th ed.) Citation

Barry, Houreratou, et al. Safety and Immunogenicity of 2-dose Heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccination in Healthy and HIV-infected Adults: A Randomised, Placebo-controlled Phase II Clinical Trial in Africa. Public Library of Science (PLoS), 2021.